Jupiter Neurosciences doses first patient in Parkinson’s disease Phase 2a trial
Jupiter Neurosciences has dosed the first patient in its Phase 2a RESET trial of JOTROL in Parkinson’s disease, marking a clinical milestone. RESET is a multicenter, randomized, double-blind, placebo-controlled study expected to enroll about 30 patients randomized 1:1:1 to two dose levels of J
<p>Jupiter Neurosciences has dosed the first patient in its Phase 2a RESET trial of JOTROL in Parkinson’s disease, marking a clinical milestone. RESET is a multicenter, randomized, double-blind, placebo-controlled study expected to enroll about 30 patients randomized 1:1:1 to two dose levels of J</p>